The Top 20 Orphan Drug Companies in 2020

In Orphan Drug Congress, Partnering & Investment by Cameron3 Comments

Big pharma will feel the heat over the next 6 years as small and mid-size developers eat away at their market share and profit margins. But as far as in-house orphan drug units go, GSK has bucked the trend and rocketed up the ranking, along with the likes of Pharmacyclics who shoot up an impressive 65 places from 2013.

Top Orphan Companies by 2020


Top Orphan Companies by 2020 Feature Image


  1. Pingback: Orphan Drugs Set To Be Worth $176 Billion in 2020 - Orphan Drugs : Orphan Drugs

Leave a Comment